Company intelligence / Profile preview
Second Life Therapeutics, Inc.
New York City, New York, United Statessltherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Second Life Therapeutics’ lead program—an allogeneic cell therapy using Teazeled receptor–activated human white blood cells—is in preclinical development for pancreatic cancer. No clinical results have been reported as of early 2025[1][4]. The company positions itself as aiming to revolutionize treatment paradigms in cancer and other areas within the “New Biology”[2][7].
- Therapeutic areas
- OncologyEndocrinologyGastroenterology
- Modalities
- Cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Second Life Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Second Life Therapeutics, Inc..